[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oxytocin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oxytocin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,71,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100404831","phase-2-oxytocin-for-weight-loss-in-adolescents-100404831",false,"NCT04551482","Oxytocin for Weight Loss in Adolescents","Oxytocin as a Neuroendocrine Therapy for Obesity in Youth","Inclusion Criteria:\n\n* Males and Females, 10-18 years\n* Obesity (BMI ≥95th percentile for age and gender)\n* Willingness to maintain current diet and lifestyle for the duration of study participation\n\nExclusion Criteria:\n\n* Current substance abuse\n* Use of prescription or over-the-counter drugs or dietary\u002Fherbal supplements that may affect weight if dose increased in the three months preceding the baseline visit and\u002For if they plan to increase the dose during the 18 weeks of study participation.\n* Greater than 5kg weight loss over 3 months;\n* Follows a nonstandard diet (e.g., Paleo, Atkins, raw diet, macrobiotic diet)\n* Cardiovascular disease\n* Prolonged QT interval\n* Chronic inflammatory bowel disease and other inflammatory conditions\n* Epilepsy\n* TSH \\> 2.5 times upper limit of normal\n* Alanine transaminase (ALT) or aspartate transaminase (AST) \\>2.5 times upper limit of normal\n* Creatinine \\>1.5 mg\u002Fdl\n* Hyponatremia\n* Pregnancy\u002Fbreastfeeding or refusal to use contraception not containing estrogen throughout the study if female and sexually active\n* MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clips\n* Weight \\>450 lbs due to limits for MRI and DXA scanners\n* Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus if HbA1c \\>8%\n* Active eating disorder","ALL","10 Years","18 Years",{"count":20,"type":21},55,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 10-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments.",[27,28],"Obesity, Adolescent","Oxytocin","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-26","ACTUAL",{"date":35,"type":33},"2021-07-28",{"date":37,"type":21},"2027-02-28",{"name":39,"class":40},"Massachusetts General Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100445392","phase-4-the-stimulation-to-induce-mothers-study-100445392","NCT05079841","The Stimulation To Induce Mothers Study","The Stimulation To Induce Mothers (STIM) Study: A Parallel Group Randomized Controlled Trial","STIM","Inclusion Criteria:\n\n* Nulliparous\n* Gestational age 36 0\u002F7 weeks and greater at enrollment\n* Singleton gestation\n* Planned to undergo initiation of exogenous oxytocin infusion by their maternity care provider\n* Spontaneous rupture of membranes or if membranes intact, modified Bishop score ≥5 and cervix dilated \\\u003C6 cm within one hour of enrollment\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Unable to understand English or Spanish\n* Prior use of exogenous oxytocin or attempt at nipple stimulation during the current pregnancy\n* Presence of tachysystole (defined as more than 5 contractions in 10 minutes averaged over 30 minutes), recurrent variable or late fetal decelerations, and bradycardia in the prior 30 minutes before enrollment\n* Non-vertex presenting fetus at time of enrollment\n* Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., placenta previa, vasa previa, active genital herpes infection, previous transmural myomectomy)\n* Multi-fetal gestation (e.g., twins, triplets, and higher-order multiples)\n* Intrauterine fetal death\n* Major fetal anomaly suspected prenatally (defined as a fetal anomaly with anticipated neonatal intensive care unit admission)\n* Suspected alloimmunization (given the increased likelihood for anticipated neonatal intensive care unit admission)\n* Known severe fetal growth restriction (estimated fetal weight \\\u003C3rd percentile) or abnormal umbilical artery Doppler studies (given the increased likelihood for anticipated neonatal intensive care unit admission)\n* HIV infection (nipple stimulation is not encouraged given the recommendation for these mothers not to breastfeed)\n* Participation in another interventional study that influences management of labor and delivery or perinatal morbidity or mortality\n* History of mastectomy or other contraindication to use of electronic breast pump\n* Known allergic reactions to components of the electronic breast pump or to synthetic oxytocin intravenous solution\n* Significantly impaired consciousness or executive function (e.g., intubated or sedated)",true,"FEMALE",{"count":53,"type":21},988,[55],"PHASE4","The investigators propose a parallel group randomized clinical trial of intrapartum nipple stimulation versus exogenous oxytocin infusion for nulliparous women undergoing induction of labor near term. The central hypothesis is that intrapartum nipple stimulation to induce labor increases spontaneous vaginal delivery, improves patient-centered outcomes such as childbirth satisfaction, labor agentry, and pain scores, and reduces adverse neonatal and maternal outcomes in nulliparous women. The investigators will pursue the following specific aims: 1) Assess the effectiveness of intrapartum nipple stimulation on the rate of spontaneous vaginal delivery in nulliparous women, 2) Breastfeeding as the sole source of nutrition at time of maternal hospital discharge (Primary Aims); 3) Maximal percent newborn weight loss during the birth hospitalization within 72 hours of life, 4) Determine the effect of intrapartum nipple stimulation on the rate of adverse maternal and neonatal outcomes, 5) Determine the impact of intrapartum nipple stimulation on patient-centered outcomes and 6) In a sub-cohort of women who are enrolled in the trial, investigators will measure the change in oxytocin concentration from baseline to time at which patient achieves a regular contraction pattern.",[28,58,59,60],"Labor Pain","Induction of Labor Affected Fetus \u002F Newborn","Physiologic Effects of Drugs","2026-03-19",{"date":63,"type":33},"2026-03-24",{"date":65,"type":33},"2021-11-15",{"date":67,"type":21},"2029-03",{"name":69,"class":40},"Yale University",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":50,"sex":51,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":95,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100619990","mindfulness-and-meditation-based-lactation-education-on-maternal-breastmilk-in-the-neonatal-icu-100619990","NCT07351799","Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU","The Impact of Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU: Intervention Study","Inclusion Criteria:\n\n* Maternal age \\> 20 years of age\n* Read, write and understand English\n* Infant NICU admit\n* Infant birthplace of Rochester, MN (Mayo Clinic)\n* Maternal adherence to pumping ≥ 8 times in 24 hours\n* Mother enrolled within 72 hours of birth\n* Gestational age of neonate at birth of \\\u003C 34 0\u002F7 weeks\n\nExclusion Criteria:\n\n* Maternal extensive existing mindfulness practice\n* Maternal breast\u002Fchest surgery\n* Maternal polycystic ovarian syndrome (PCOS)\n* Maternal current illicit substance abuse\n* Diagnosis of maternal current severe mental health concerns\n* Maternal multiple gestation (twins or higher order) pregnancy and delivery","20 Years",{"count":80,"type":21},40,[82],"NA","The purpose of this research is to investigate associations between mindfulness and meditation techniques and changes in maternal breastmilk in the mother pumping for her NICU infant.",[85,86,87,88,89,90,91,92,28,93,94],"Lactation","Mindfulness","NICU","Breastmilk","Neonatal","Meditation","Pumping, Breast","Cortisol","Anxiety","Depression",[96,97,87,98,89,99,100,101,102,103,94],"lactation","mindfulness","breastmilk","meditation","pumping, breast","cortisol","oxytocin","anxiety","2026-01-12",{"date":106,"type":33},"2026-01-20",{"date":108,"type":33},"2025-09-22",{"date":110,"type":21},"2026-11-02",{"name":112,"class":40},"Mayo Clinic",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":51,"minAge":78,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":41},"100516886","phase-3-comparing-intramyometrial-tranexamic-acid-and-oxytocin-for-blood-loss-in-cesarean-section-100516886","NCT06010368","Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section","The Effect of Intramyometrial Tranexamic Acid Versus Intramyometrial Oxytocin in Reducing Blood Loss During and After Elective Cesarean Section in Term Primigravida: A Double-blinded, Randomized, Comparative-placebo Trial","nclusion Criteria:\n\n* Women booked for a primary elective cesarean section, not in active labor\n* Aged between 20-40 years.\n* BMI 18.5-29.9 kg\u002F m2 pre-pregnancy weight\n* Term pregnancies (Early term: between 37 weeks, 0 days and 38 weeks, 6 days. Full term: between 39 weeks, 0 days and 40 weeks, 6 days. Late term: between 41 weeks, 0 days and 41 weeks, 6 days).\n* Singleton pregnancies.\n* Indication of elective cesarean section (Malpresentation, Malposition, Cephalopelvic disproportion, active herpes)\n* Fetal macrosomia (Macrosomia is defined as birth-weight over 4,000 g irrespective of gestational age)\n* Certain congenital fetal malformation and skeletal disorders (Several congenital anomalies are controversial indications for cesarean delivery; these include fetal neural tube defects (to avoid sac rupture), particularly defects that are larger than 5-6 cm in diameter as anterior cystic hygroma vascular sacrococcygeal teratoma, giant omphalocele and hydrocephalus with an enlarged biparietal diameter, and some skeletal dysplasia such as type III osteogenesis imperfecta. (Hamrick et al., 2008)\n\nExclusion Criteria:\n\n* Placenta previa.\n* Maternal hypertension and Preeclampsia.\n* Diabetes mellitus.\n* Severe medical disorder (renal or hepatic).\n* Multiple Fibroid uterus.\n* Multiple pregnancies.\n* Polyhydramnios.\n* Previous uterine surgery as myomectomy.\n* Contraindication to spinal anesthesia.\n* Blood coagulopathy and bleeding disorder.\n* Marked maternal anemia (Preoperative hemoglobin \\\u003C9 gm\u002Fdl).\n* Contraindications to TXA or oxytocin therapy (e.g. allergy)","40 Years",{"count":122,"type":21},150,[124],"PHASE3","Cesarean section is the most prevalent operation among women globally, 10-15% (1, 2). Recent research has shown Egypt to be the third-largest country globally, with an estimated 52% cesarean sections (3). However, the cesarean section has many serious complications, including the primary postpartum hemorrhage (PPH) (4). During labor, the average blood loss is about 300 to 400 ml. Bleeding postpartum is known as losing over five hundred milliliter of blood following a vaginal birth and losing over one thousand milliliter after the cesarean section (5). The prime cause of maternal death rate is postpartum bleeding, predominately in poor countries, and the estimated mortality number due to postpartum bleeding is one hundred thousand per year (6). Therefore, it is essential to reduce bleeding during and after CS to diminish maternal mortality and morbidity (7). The most successful technique for decreasing PPH is the active third stage labor management, requiring prophylactic uterotonic drugs like oxytocin, ergometrine malate, prostaglandins (E1, E2, and F2α), and combinations of them, or hemostatic agent as tranexamic acid (Kapron) and Etamsylate (Dicynon) (8, 9).",[127,128,28,129],"Cesarean Section Complications","Tranexamic Acid","Post Partum Hemorrhage","NOT_YET_RECRUITING","2024-09-02",{"date":133,"type":33},"2024-09-05",{"date":135,"type":21},"2024-10-01",{"date":137,"type":21},"2026-01-01",{"name":139,"class":40},"Cairo University"]